Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
UroGen Pharma Ltd (NASDAQ: URGN) closed the day trading at $24.35 down -0.12% from the previous closing price of $24.38. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 0.73 million shares were traded. URGN stock price reached its highest trading level at $25.83 during the session, while it also had its lowest trading level at $24.27.
Ratios:
For a better understanding of URGN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.79 and its Current Ratio is at 3.99.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $36.
On June 16, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’25 when Schoenberg Mark sold 10,000 shares for $25.00 per share. The transaction valued at 250,000 led to the insider holds 139,025 shares of the business.
Schoenberg Mark bought 10,000 shares of URGN for $250,005 on Nov 19 ’25. On Oct 08 ’25, another insider, Degnan Chris, who serves as the Chief Financial Officer of the company, sold 2,203 shares for $16.85 each. As a result, the insider received 37,121 and left with 2,280 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, URGN now has a Market Capitalization of 1139796480 and an Enterprise Value of 1142703488. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.81. Its current Enterprise Value per Revenue stands at 11.84 whereas that against EBITDA is -8.716.
Stock Price History:
The Beta on a monthly basis for URGN is 1.30, which has changed by 0.996724 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, URGN has reached a high of $30.00, while it has fallen to a 52-week low of $3.42. The 50-Day Moving Average of the stock is 16.57%, while the 200-Day Moving Average is calculated to be 62.07%.
Shares Statistics:
Over the past 3-months, URGN traded about 1.20M shares per day on average, while over the past 10 days, URGN traded about 1100520 shares per day. A total of 46.78M shares are outstanding, with a floating share count of 38.62M. Insiders hold about 17.50% of the company’s shares, while institutions hold 93.13% stake in the company. Shares short for URGN as of 1763078400 were 8976703 with a Short Ratio of 7.46, compared to 1760486400 on 11148494. Therefore, it implies a Short% of Shares Outstanding of 8976703 and a Short% of Float of 19.469998999999998.
Earnings Estimates
The market rating of UroGen Pharma Ltd (URGN) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.36 and low estimates of -$0.63.
Analysts are recommending an EPS of between -$2.64 and -$3.4 for the fiscal current year, implying an average EPS of -$3.13. EPS for the following year is -$0.6, with 7.0 analysts recommending between $2.44 and -$1.73.
Revenue Estimates
8 analysts predict $41.45M in revenue for. The current quarter. It ranges from a high estimate of $51.57M to a low estimate of $32.86M. As of. The current estimate, UroGen Pharma Ltd’s year-ago sales were $24.57MFor the next quarter, 8 analysts are estimating revenue of $43.62M. There is a high estimate of $46.88M for the next quarter, whereas the lowest estimate is $40.1M.
A total of 8 analysts have provided revenue estimates for URGN’s current fiscal year. The highest revenue estimate was $123.52M, while the lowest revenue estimate was $104.81M, resulting in an average revenue estimate of $113.4M. In the same quarter a year ago, actual revenue was $90.4MBased on 8 analysts’ estimates, the company’s revenue will be $252.92M in the next fiscal year. The high estimate is $391.48M and the low estimate is $191.1M.
